NCT05965388Not yet recruiting
Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy
Source: ClinicalTrials.gov · Last updated 28 Jul 2023 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this prospective, exploratory, non-intervention, multi-center, real-world study is to investigate the predictive value of HBV pgRNA in the occurrence of long-term outcomes under antiviral therapy in patients with chronic hepatitis B. Participants will take the necessary clinical examination and blood draw during the patient's treatment and follow-up, and all the treatment is determined by clinicians.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 5000 (estimated)
- First submitted
- 28 Jun 2023
- Start date
- 1 Dec 2023
- Primary completion date
- 1 Feb 2029
- Lead sponsor
- Wen-hong Zhang
- Diseases
- Hepatitis B
- NCT number
- NCT05965388
What you commit to
- Study type: Observational
- Planned participants: 5000
- From 1 Dec 2023 to the primary completion date, 1 Feb 2029
- 10 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with malignancies other than hepatocellular carcinoma.
Who the study is looking for
- CHB defined as positive hepatitis B surface antigen at least 6 months, or HBV-related histological changes within 1 year if HBsAg positive less than 6 months;
- Age between 18-80 years, gender is not limited；
- Patients with chronic hepatitis B who have been determined by clinicians to start, or have already taken the first-line treatment {including pegylated interferon \[IFN\] monotherapy, a potent nucleos(t)ide analogue \[NA\] monotherapy, two different potent NAs combination therapy, or NA plus IFN combination therapy;
- Patient who reads and signs informed consent.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (10)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The First Affiliated Hospital of Fujian Medical University Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
| The First Affiliated Hospital of Anhui Medical University Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
| Shandong Provincial Hospital of Shandong University Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
| The First People's Hospital of Yunnan Coordinator of this site? Confirm its status | Kunming | China | Unknown status |
| Jiangsu Province Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
| Huashan Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| The Third People's Hospital of Taiyuan Coordinator of this site? Confirm its status | Taiyuan | China | Unknown status |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Coordinator of this site? Confirm its status | Wuhan | China | Unknown status |
| First Affiliated Hospital Xi'an Jiaotong University Coordinator of this site? Confirm its status | Xi’an | China | Unknown status |
| the Affiliated Hosptial of Xuzhou Medical University Coordinator of this site? Confirm its status | Xuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.